The adenylate cyclase (CyaA) of Bordetella pertussis is able to deliver CD8 + T cell epitopes into the cytosol of CD11b + dendritic cells (DC) following its speci®c interaction with the a M b 2 integrin (CD11b/CD18). This delivery results in intracellular processing and presentation by MHC class I molecules of the CD8 + T cell epitopes inserted into CyaA. Indeed, we previously showed that CyaA toxins carrying a single cytotoxic T lymphocyte (CTL) epitope can induce ef®cient protective and therapeutic antitumor immunity in mice. With a view to elaborating cancer immunotherapy in humans using CyaA, we constructed two recombinant CyaA carrying HLA*0201-restricted melanoma epitopes. Here we show that these recombinant CyaA induce strong anti-melanoma CTL responses in HLA*0201 transgenic mice, even after a single i.v. immunization without adjuvant. These responses are long lasting, since they were also detected 5 months after the last injection. Finally, human DC treated with the recombinant CyaA were shown to process and present ef®ciently the melanoma epitopes to human CTL clones. Altogether, our results demonstrate that tumoral epitopes inserted into CyaA are ef®ciently processed and presented in association with human MHC molecules. These observations suggest that CyaA is capable of activating antitumoral CTL in humans and highlight the potential of CyaA for use in cancer immunotherapy.
Introduction
T cells play an important role in tumor rejection in many animal tumor models, and a variety of tumor antigens recognized by CD4 + or CD8 + tumor-reactive T cells have been identi®ed both on murine and human tumors (1) . CD8 + cytotoxic T lymphocytes (CTL) are of particular interest since these cells speci®cally recognize tumor cells and kill them. An important goal in cancer immunotherapy is therefore to activate tumorspeci®c CTL. The study of antigens recognized by CD8 + T cells on human melanoma has resulted in the molecular identi®cation of several MHC-restricted tumor epitopes (2) which correspond to non-mutated or mutated peptides derived from various self-proteins. Among these peptides, several are derived from non-mutated differentiation proteins such as tyrosinase (Tyr), Melan-A/Mart-1 and gp100. These proteins are speci®cally expressed in most melanocytes/ melanomas and thus the HLA-restricted epitopes are presented by most melanoma cells from patients expressing the relevant HLA molecules. These antigens could therefore constitute the targets of immunotherapeutic strategies based on immunization against tumor epitopes. Others antigens expressed on tumoral cells were also described, such as a peptide derived from an intron sequence of the gene that codes for N-acetylglucosaminyl-transferase V (GnT-V) (3) . This intron is speci®cally expressed in melanoma cells and is present in~50% of melanoma cells, and thus induction of CTL against this epitope could be very useful in immunotherapy.
Various vaccination protocols designed to induce speci®c antitumor CTL responses against these epitopes have been developed, including the use of free peptide in incomplete Freund's adjuvant (4) , recombinant viral vectors (5±7) or dendritic cells (DC) (8±11). Nevertheless, the application of these approaches to human vaccination remains limited due to the potential toxicity of adjuvants, bias towards the response against vector-derived epitopic peptide or because they are`labor-intensive' (in vitro manipulated DC). Additionally, the availability of different immunotherapeutic strategies will be of interest to amplify speci®cally CTL responses against tumoral antigens while controlling those directed at vector-derived epitopes using several vectors carrying the same tumor epitopes.
A new approach for CTL activation has recently been developed based on bacterial toxins capable of delivering antigenic epitopes across the plasma cell membrane into the cytosol, where appropriate processing and interaction with MHC class I molecules can occur. The adenylate cyclase (CyaA) toxin of Bordetella pertusis has the capacity to deliver its catalytic domain into the cytosol of eukaryotic cells (12) . Delivery of a CD8 + T cell epitope inserted into the catalytic site of CyaA results in intracellular processing and presentation of the epitope by MHC class I molecules at the surface of antigen-presenting cells (APC) (13) . Furthermore, we recently demonstrated that the CyaA speci®cally binds to the a M b 2 integrin (CD11b/CD18) (14) and thus targets the CD11b + DC subpopulation, which very ef®ciently induces primary immune responses (15) . Thus, immunization of mice with a recombinant CyaA toxin bearing a viral epitope led to the induction of strong CTL responses and to full protection against a lethal viral challenge (16) . Moreover, CyaA toxins carrying a single CTL epitope could also stimulate ef®cient protective and therapeutic antitumor immunity in mice (17) . Importantly, genetically detoxi®ed CyaA toxoids retain the property to induce protective antiviral or antitumoral immunity (17, 18) . Thus, CyaA seems to be a safe and ef®cient non-replicating vector to induce speci®c immune responses in mice. However, with a view to elaborating cancer immunotherapy using CyaA, it is of particular importance to demonstrate that human tumoral epitopes inserted into CyaA are ef®ciently processed and presented in association with human MHC molecules. To that end, we constructed two recombinant CyaA carrying HLA*0201-restricted melanoma epitopes derived either from Tyr or GnT-V. In this study, we evaluated the potency of these recombinant CyaA to induce in vivo HLA*0201-restricted CTL responses against the inserted epitopes and the ability to deliver these epitopes to human APC.
Methods

Mice
HHD mice are H-2D ±/± b 2 m ±/± double-knockout mice expressing the HHD transgene comprising the a1 (H) and a2 (H) domains of HLA*0201 linked to the a3 transmembrane and cytoplasmic domains of H-2D b (D), with the a1 domain linked to human b 2 -microglobulin. Thus, the only MHC class I molecule expressed by the HHD mice is the modi®ed HLA*0201 molecule (19) . HHD mice were bred and housed in the animal facilities of the Pasteur Institute.
Peptides
The synthetic peptides pTyr (YMDGTMSQV) corresponding to the melanoma HLA*0201-restricted epitope from the 369±377 region of Tyr (20, 21) and pGnT-V (VLPDVFIRC) corresponding to the HLA*0201-restricted epitope NA17-A derived from an intron of the GnT-V gene (3) were purchased from Neosystem (Strasbourg, France).
Construction of recombinant B. pertussis CyaA toxins and toxoids carrying melanoma epitopes
Recombinant CyaA toxin CyaA-Tyr harbors a 14-amino-acid long polypeptide sequence (PASYMDGTMSQVGT, one-letter code for amino acid) genetically inserted between residues 224 and 235 of CyaA. This sequence contains a single copy of the HLA*0201-restricted melanoma epitope derived from Tyr (amino acid 369±377, underlined sequence above). Recombinant CyaA toxin CyaA-GnT-V harbors a 14-aminoacid long (PASVLPDVFIRCGT) insert at the same position and contains a single copy of the HLA*0201-restricted melanoma epitope NA17-A derived from the GnT-V gene (underlined sequence above).
These recombinant toxins were produced in the Escherichia coli strain BLR (Novagen, Madison, WI) by using expression vectors that are derivatives of the pTRACG plasmid (22) , modi®ed by insertion between the NheI and KpnI restriction sites of appropriate synthetic double-stranded oligonucleotides encoding the indicated polypeptide sequences (nucleotide sequences are available upon request). The E. coli strain XL1-Blue (Stratagene, La Jolla, CA) was used for all DNA manipulations that were performed according to standard protocols. The recombinant proteins were puri®ed to homogeneity from inclusion bodies by a two-step procedure that includes DEAE±Sepharose and phenyl±Sepharose chromatography, as described previously (23) .
The recombinant toxins CyaA-Tyr and CyaA-GnT-V are enzymatically active and therefore cytotoxic. The recombinant toxoids CyaA-E5-Tyr and CyaA-E5-GnT-V are enzymatically inactive, detoxi®ed variants of CyaA-Tyr and CyaA-GnT-V respectively. They are unable to synthesize cAMP as a result of a dipeptide insertion within a critical region of the catalytic site (23) . CyaA-E5-Tyr and CyaA-E5-GnT-V toxoids were produced in E. coli by using expression vectors that are derivatives of the pTRACE5 plasmid: this plasmid was obtained by insertion of the hexanucleotide CTGCAG in an EcoRV site located in the 5¢ part of the cyaA DNA sequence. This results in an in-frame insertion of the dipeptide Leu±Gln between Asp188 and Ile189 of CyaA (23) . The same synthetic double-stranded oligonucleotides described above were inserted between the NheI and KpnI sites of pTRACE5 to create plasmids pTRAC-E5-Tyr and pTRAC-E5-GnT-V. The recombinant CyaA-E5-Tyr and CyaA-E5-GnT-V toxoids were puri®ed to homogeneity as described (23) .
All puri®ed recombinant toxins and toxoids were >90% pure as judged by SDS±PAGE analysis (not shown). The toxin concentrations were determined spectrophotometrically from the absorption at 280 nm using a molecular extinction coef®cient of 142,000 M ±1 cm ±1 .
Oligonucleotide synthesis and DNA sequencing were performed by Genaxis (Nimes, France). Cultures in fermentors were performed by the`Service des Fermentations' facility from the Pasteur Institute.
Mouse immunization
Female HHD mice (6±10 weeks old) were immunized with two or three i.p. injections at 21-day intervals of either 50 mg CyaA or recombinant CyaA carrying melanoma epitopes in the presence or in the absence of 1 mg alum. In some experiments, mice were immunized with one i.v. injection of 50 mg of the recombinant CyaA in PBS. Detoxi®ed recombinant CyaA-E5 was used in the same conditions. Spleens were surgically removed 7 days after the last injection except for the analysis of long-lasting responses, where spleens were removed 3 or 5 months after the last injection.
In vitro cytotoxic assay
Spleen cells from immunized mice were stimulated in vitro with 10 mg/ml of pTyr or pGnT-V peptides corresponding to the priming epitope in the presence of syngeneic irradiated naive spleen cells in complete medium (RPMI 1640 medium containing L-Ala±L-Glu dipeptide supplemented with 10% FCS, 5 Q 10 ±5 M 2-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml streptomycin and 20 mM HEPES) during 5 days. The cytotoxic activity of these effector cells was tested in a 4-h 51 Cr-release assay on HHD transfected TAP ±/± RMA-S cells (RMA-S-HHD) loaded with the relevant peptides as target cells. 51 Cr-labeling was performed as follows: 1 day before the cytotoxic test, RMA-S-HHD cells were incubated overnight at room temperature in 7% CO 2 equilibrated RPMI 1640 medium supplemented with 20 mM HEPES. Then, cells were incubated 3 h at room temperature with or without 20 mg/ml of the relevant peptide, washed once and radiolabeled with 100 mCi of 51 Cr for 1 h at 37°C.
Various E:T ratios were used and all assays were performed in duplicate. The radioactivity released in the supernatant of each well was measured. The percentage of speci®c lysis was calculated as 100 Q (experimental release ± spontaneous release)/(maximum release ± spontaneous release). Maximum release was generated by adding 10% Triton X-100 to target cells and spontaneous release was obtained with target cells incubated in medium alone. Mice are considered as responders when at least 20% speci®c lysis was observed at the highest E:T ratio. Results are expressed as means T SD of responder mice per group. No speci®c CTL activity was obtained with splenocytes from immunized mice stimulated in vitro with an irrelevant peptides.
Human DC
Human DC were derived from adherent monocytes as follows. Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats obtained from the HLA*0201 hemochromatosis patient LB2050 by centrifugation on Leucosep tubes (Greiner, Frickenhausen, Germany) previously centrifuged 30 s at 2200 r.p.m. with 15 ml of Lymphoprep (Nycomed Pharma, Oslo, Norway). These tubes were centrifuged at 2200 r.p.m. for 20 min at room temperature and the top part containing plasma was discarded. The interphase containing the PBMC was harvested and washed at least 3 times in cold phosphate buffer with 1 mM EDTA in order to eliminate the remaining platelets. The PBMC were then left to adhere for 1 h in culture¯asks at a density of 2 Q 10 6 cells/cm 2 in RPMI 1640 supplemented with amino acids (L-arginine 116 mg/ml, Lasparagine 36 mg/ml and L-glutamine 216 mg/ml), antibiotics and 10% FCS (hereafter referred as culture medium). Nonadherent cells were discarded, adherent cells were washed twice carefully with 20 ml of medium, and incubated in culture medium with 200 U/ml human IL-4 and 70 ng/ml human granulocyte macrophage colony stimulating factor (GM-CSF). On days 2 and 4, 5 ml of medium was removed and 10 ml of culture medium containing 700 ng of GM-CSF was added. IL-4 was also supplemented at 200 U/ml for the total volume of thē ask. The cells were used between days 5 and 7.
Human CTL clones CTL clone IVS-B directed against the HLA*0201-restricted Tyr epitope (positions 369±377) of Tyr was previously described (24) . It was weekly stimulated with 50 U/ml human IL-2, irradiated HLA*0201 transfected MZ2-MEL melanoma cells pulsed with 2 mg/ml pTyr peptide and irradiated LG2-EBV cells as feeder cells. The CTL clone CMU 579 6/3 speci®c for the HLA*0201-restricted epitope derived from GnT-V was obtained from the blood of a healthy donor following a recently described method (25) . Brie¯y, the PBMC were stimulated for 2 weeks with the antigenic peptide pGnT-V, human IL-2, IL-4 and IL-7. On day 13, PBMC were stained with an HLA*0201 tetramer folded with the pGnT-V peptide. Tetramer + lymphocytes were cloned using¯ow cytometry. They were stimulated for 2 weeks with irradiated allogeneic HLA*0201 + Epstein±Barr virus-transformed B cells pulsed with the peptide, irradiated allogeneic peripheral blood lymphocytes, IL-2, IL-4 and IL-7, and then maintained by weekly stimulation with irradiated HLA*0201 + peptide-pulsed allogeneic tumor cells and irradiated allogeneic Epstein±Barr virus-transformed B cells. Both CTL clones were maintained in Iscove's medium supplemented with 10% of human serum, amino acids and antibiotics.
In vitro stimulation assay of human CTL clones
For the stimulation assay, 10 4 immature DC were seeded in Ubottom microplates in 25 ml of X-Vivo 10 medium (Whittaker Bioproducts, Walkersville, MD). CyaA preparations (25 ml) diluted in X-Vivo 10 medium at different concentrations were added to the wells. After 30 min of incubation, the corresponding CTL clones were incubated with these cells (75 ml of X-vivo medium containing 10 4 anti-Tyr CTL clone IVS-B or 104 anti-GnT-V CTL clone CMU 579 6/3) and IL-2 (at a ®nal concentration of 25 U/ml). The supernatants were collected after 20 h and IFN-g content determined by ELISA (Biosource, Camarillo, CA). To control the ability of DC incubated with the various detoxi®ed recombinant toxoids to stimulate the CTL clones, they were exogenously loaded with the relevant antigenic peptides, incubated with the relevant CTL clones and the production of IFN-g was similarly assessed (data not shown).
Results
Induction of melanoma-speci®c CTL responses by immunization of HHD transgenic mice with recombinant CyaA carrying HLA*0201-restricted melanoma epitopes
To determine whether the CyaA toxin is capable of inducing speci®c CTL responses against human tumoral antigens, two recombinant CyaA carrying HLA*0201-restricted human melanoma epitopes were constructed. The ®rst recombinant CyaA expresses the epitope 369±377 from the Tyr antigen (CyaATyr) and the second one expresses the epitope NA17-A derived from an intron of GnT-V (CyaA-GnT-V). The ability of recombinant CyaA to induce CTL responses against these two epitopes in vivo was assessed in HHD mice, which are transgenic for the human MHC class I molecule HLA*0201 and have been shown to develop HLA*0201-retricted CTL responses against tumoral peptides (26) . HHD mice were immunized by three i.p. injections of 50 mg of recombinant CyaA with alum. After in vitro stimulation of splenocytes with the corresponding peptide, CTL responses were tested in a 51 Cr-release assay, using as targets peptide-pulsed RMA-S-HHD cells, which express the same transgene as HHD mice.
As shown in Fig. 1 , both recombinant toxins carrying either Tyr or GnT-V epitopes induce strong CTL responses against target cells loaded with the relevant peptide. These CTL responses were antigen speci®c, since only peptide-sensitized target cells were killed and CTL activity was not detected on target cells loaded with irrelevant peptides (data not shown). As expected, no signi®cant CTL responses were observed in mice immunized with the wild-type CyaA, showing that the induction of speci®c CTL responses required in vivo priming by the epitope inserted into recombinant CyaA. Induction of CTL responses by CyaA-Tyr was then analyzed using different immunization protocols with or without alum as adjuvant. As illustrated in Fig. 2(A and B) , two i.p. injections of CyaA-Tyr were enough to induce speci®c CTL responses against the Tyr epitope, even in the absence of alum. Induction of strong, speci®c CTL responses was also observed following a single injection of 50 mg of CyaA-Tyr without adjuvant using the i.v. route (Fig. 2C) . As expected, these CTL responses were observed only when using peptide-pulsed target cells and splenocytes from mice immunized with the recombinant CyaA-Tyr, showing the speci®city of the responses. These results demonstrate the high ef®ciency of CyaA-Tyr to induce speci®c CTL responses against the Tyr melanoma epitope.
However, using similar conditions of immunization (two or one i.p. injections with or without alum), no speci®c CTL response was observed with the recombinant toxin CyaA-GnT-V, indicating that this toxin is less ef®cient in generating a speci®c CTL response than the CyaA-Tyr (data not shown). However, using the i.v. route, one injection of CyaA-GnT-V was suf®cient to induce a strong CTL response (Fig. 2E) .
Finally, we also analyzed CTL responses induced by genetically detoxi®ed mutants of CyaA carrying Tyr or GnTV epitopes that are devoid of CyaA activity following insertion of a dipeptide into the catalytic site. HHD mice immunized with these detoxi®ed molecules developed speci®c CTL responses against both Tyr and GnTV epitopes (Fig. 2D and F) , which were comparable to the responses of mice immunized with the toxic forms of CyaA carrying the corresponding epitope. These results indicate that HLA*0201-restricted CTL induction is independent of the catalytic activity as it was clearly demonstrated for a viral epitope from LCMV in BALB/C mice (18) .
Recombinant CyaA-Tyr induces long-lasting memory CTL responses
To analyze the persistence of the CTL responses induced by the recombinant CyaA-bearing melanoma epitope, HHD mice received two i.p. injections of 50 mg of CyaA-Tyr in the presence of alum. At 3 and 5 months after the last injection, splenocytes from immunized mice were stimulated in vitro during 5 days with the peptide pTyr and then their cytolytic activity was tested against peptide-pulsed RMA-S-HHD target cells. As illustrated in Fig. 3 , CyaA-Tyr induced a long-lasting speci®c CTL response since speci®c cytotoxic activity could be detected in all mice 3 months after the last injection and even after 5 months in one animal.
HLA*0201-restricted peptides inserted into CyaA are processed and presented by HLA*0201 + human DC In vivo induction of speci®c CTL responses by recombinant CyaA indicates that inserted epitopes are ef®ciently processed and presented by murine APC. However, it is important to demonstrate that human APC are also able to process and present these HLA*0201-restricted epitopes inserted into CyaA. Since DC are the most important APC to induce primary T cell responses, we determined the ability of HLA*0201 + DC incubated with the recombinant CyaA to stimulate human CTL clones speci®c for the epitopes inserted into the recombinant CyaA. For these experiments, human DC were generated in vitro from HLA*0201 + adherent PBMC in the presence of GM-CSF and IL-4. Increasing doses of CyaA-E5-Tyr, CyaA-E5-GnT-V or control CyaA-E5 were then added, and presentation of the antigenic peptides was assessed by measuring the ability of the treated DC to stimulate the relevant CTL in an IFN-g production assay. As shown in Fig. 4(A) , human DC incubated with CyaA-E5-Tyr induced a high production of IFNg by the Tyr-speci®c CTL clone, indicating that the Tyr epitope is ef®ciently processed and presented in association with HLA*0201 molecules. The speci®city of this recognition was con®rmed by the lack of stimulation of two irrelevant CTL clones (data not shown) and by the lack of stimulation of the Tyr-speci®c clone by DC treated with the control toxoid CyaA-E5 (Fig. 4A) . Presentation of the Tyr epitope was proportional to the dose of CyaA-Tyr up to 30 nM. In our conditions, higher doses appeared to be toxic for the DC, as indicated by the low recognition of the treated DC and by their decreased ability to present the synthetic peptide loaded exogenously (data not shown). In order to assess the relative ef®ciency of antigen presentation using CyaA as a delivery system, we also produced a titration curve of the Tyr synthetic peptide, which we pulsed on similar DC. As shown in Fig. 4(A) , CyaA-Tyr was up to 100 times more ef®cient than the synthetic peptide in inducing the presentation of the epitope by DC.
Human DC incubated with CyaA-E5-GnT-V induced a weak, but reproducible, production of IFN-g by the GnT-V-speci®c CTL clone, as compared with DC incubated with the peptide pGnT-V (Fig. 4B ). This result indicates that human DC are able to present the GnT-V epitope inserted into CyaA, although with a moderate ef®ciency.
Altogether, our results clearly demonstrate the capacity of human DC to process and present human epitopes inserted into CyaA.
Discussion
The CyaA of B. pertussis represents a new delivery system able to speci®cally stimulate CD8 + T lymphocytes leading to protective antiviral and antitumoral immunity in mice (16, 17) . This indicates that CyaA is a powerful non-replicating vector for induction of adaptive immunity and might potentially be used for vaccine design. However, demonstration that the inserted epitopes can be processed and presented in association with human MHC molecules is an indispensable prerequisite for the use of this vector in humans. In this report, using recombinant CyaA in which human melanoma epitopes were inserted, we showed that strong and long-lasting melanoma-speci®c CTL responses could be induced in HHD mice expressing the human HLA*0201 class I molecule. Similar results were obtained with recombinant detoxi®ed CyaA devoid of CyaA activity. CyaA represents an ef®cient vector to induce speci®c CTL responses in vivo since >80% of immunized HHD mice respond to the Tyr epitope inserted into CyaA following one i.v. injection without adjuvant, while only 26% of HHD mice respond to this epitope following one injection of 100 mg of peptide in the presence of incomplete Freund's adjuvant [(26) and data not shown]. We also showed that human DC ef®ciently processed these recombinant molecules for antigenic peptide presentation to human CTL. Strikingly, the recombinant CyaA-Tyr was much more ef®cient than the synthetic peptide in delivering the Tyr epitope to DC. Alternative antigen delivery systems, e.g. based on recombinant viruses, usually result in an in vitro presentation ef®ciency that is lower than the synthetic peptide. Our results from in vivo and in vitro experiments therefore underline the power of CyaA as a delivery system, and suggest that CTL responses could be obtained in humans after immunization with recombinant CyaA and thus that ef®cient immunotherapy could be achieved with this vector. However, the immunogenicities of the two recombinant CyaA tested in this study were quite different. Indeed, strong CTL responses in HHD mice were induced with only one i.p. injection of CyaA-Tyr in the absence of adjuvant, while three i.p. injections of CyaA-GnT-V in the presence of alum were required to generate speci®c CTL responses. The weak ef®ciency of CyaA-GnT-V to deliver GnT-V melanoma epitope was also evidenced in vitro, since human DC incubated with this vector poorly stimulated an anti-GnT-V CTL clone as compared to CyaA-Tyr, which stimulated ef®ciently a speci®c anti-Tyr CTL clone. This difference could be explained by the fact that the GnT-V peptide grafted into CyaA-GnT-V was poorly processed as compared to the Tyr peptide inserted into CyaA-Tyr. Indeed,¯anking regions of a given epitope are known to in¯uence the proteolytic generation of the mature peptide (27±29), particularly for subdominant and/or cryptic epitopes (30) . Thus, we can expect that modi®cation of the molecular context of GnT-V epitope into CyaA could enhance the ef®ciency of processing of this epitope by APC. On the contrary, the sequence¯anking the Tyr epitope in CyaA-Tyr appears to allow its ef®cient processing.
Furthermore, we observed that CyaA-Tyr is very ef®cient in activating HLA*0201-restricted CD8 + T cells in vivo since a single i.v. immunization or two i.p. injections without adjuvant were suf®cient to generate strong speci®c CTL responses. This could be explained by the fact that CyaA targets speci®cally CD11b + DC, the most potent APC to induce the primary response, as a result of its interaction with the a M b 2 integrin expressed by these cells (14) . Thus, CyaA has the exceptional property of being able to speci®cally deliver antigens to the cytosolic antigen class I-presentation pathway of professional APC.
Further improvements of the CyaA recombinant strategy are conceivable. First, multiple insertion of CD8 + T cell epitopes into the same recombinant molecule has already been successfully achieved. Indeed immunization of mice with recombinant CyaA carrying three different epitopes, including a LCMV epitope, led to the induction of speci®c CTL responses for each of the three epitopes, as well as protection against a lethal LCMV challenge (31) . Detoxi®ed CyaA carrying multiple melanoma epitopes are under evaluation and such recombinant molecules could constitute a good alternative to induce multispeci®c CTL responses. Furthermore, additional insertion of CD4 + T cell epitopic peptides is also considered. Although the implication of CD8 + T cells in eradication of established tumors has been clearly demonstrated (32) , T h cells could be also required to induce ef®cient antitumoral responses (33±35). We have recently demonstrated that recombinant CyaA can also deliver epitopes into the MHC class II-processing pathway (36) , and are able to induce in vivo both speci®c T h 1 and CTL responses (37) . This characteristic is of great interest for vaccination strategies where both kinds of T cell responses have to be induced, noticeably in the context of cancer immunotherapy.
